Abstract
Countries with emerging pharmaceutical market (pharmerging countries) has gained prominence in the international scenario because they are identified as the future responsible for the sustainable growth of the new medicines sale. In this work, a technological and industrial mapping was developed through the analysis of patent data extracted from the Derwent World Patent Index, as well as an association with R&D reports. Pharmerging countries were not represented by the industries that most invest in R&D, nor do they stand out in patent protection, poiting to low exploitation of their markets and inexpressive innovation indices. It is suggested that the pharmerging countries adopt public policies aimed at the innovation generation, especially in the biopharmaceutical segment that has proven to have much to be explored, in order to gain a competitive advantage
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal on Innovation and Sustainability. RISUS ISSN 2179-3565
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
